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Abstract
The state of Kentucky has the highest cancer incidence and mortality in the United 
States. High- risk populations such as this are often underrepresented in clinical trials. 
The study aims to do a comprehensive analysis of molecular landscape of metastatic 
cancers among these patients with detailed evaluation of factors affecting response 
and outcomes to immune checkpoint inhibitor (ICI) therapy. We performed a retro-
spective analysis of metastatic solid tumor patients who received ICI and underwent 
molecular profiling at our institution.
Sixty nine patients with metastatic solid tumors who received ICI were included in the study. 
Prevalence of smoking and secondhand tobacco exposure was 78.3% and 14.5%, respectively. 
TP53 (62.3%), CDKN1B/2A (40.5%), NOTCH and PIK3 (33.3%) were the most common al-
terations in tumors. 67.4% were PDL1 positive and 59.4% had intermediate- high tumor muta-
tional burden (TMB). Median TMB (12.6) was twofold to fourfold compared to clinical trials. 
The prevalence of mutations associated with smoking, homologous recombinant repair and 
PIK3/AKT/mTOR pathway mutations was higher compared to historic cohorts.
PDL1 expression had no significant effect on radiologic response, but PFS improvement in 
patients with tumors expressing PDL1 trended toward statistical significance (median 18 vs. 
40 weeks. HR = 1.43. 95%CI 0.93, 4.46). Median PFS was higher in the high- TMB cohort com-
pared to low- intermediate TMB (median not reached vs. 26 weeks; HR = 0.37. 95%CI 0.13, 
1.05). A statistically significant improvement in PFS was observed in the PIK3 mutated cohort 
(median 123 vs. 23 weeks. HR = 2.51. 95%CI 1.23, 5.14). This was independent of tumor 
mutational burden (TMB) status or PDL1 expression status. PIK3 mutants had a higher overall 
response rate than the wild type (69.6% vs. 43.5%, OR 0.34; p = 0.045). The results should 
prompt further evaluation of these potential biomarkers and more widespread real- world data 
publications which might help determine biomarkers that could benefit specific populations.
K E Y W O R D S
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1 |  BACKGROUND
Kentucky has the highest cancer incidence and mortality rates 
in the country with mortality rates nearly 50% higher than the 
national average.1 Although this has been mainly attributed 
to the high- smoking prevalence in the state, economic, and 
health care disparities, and genetic factors also play a key 
role. High- risk populations such as this are often underrep-
resented in clinical trials. This could be the reason behind 
variation of smoking status, predictive biomarkers and tumor 
genomic alteration between real- world and clinical trials.2
Immune checkpoint inhibitors (ICI) were developed to 
counter the upregulation of immune checkpoints by tumors 
by targeting programmed cell death protein (PD- 1)/pro-
grammed death- ligand 1 (PDL- 1) or common T lymphocyte 
antigen- 4 (CTLA- 4), resulting in recognition and killing 
of tumor cells by the host immune system. There are over 
two dozen FDA- approved indications for this class of drugs 
currently, and they are being increasingly studied in various 
clinical trials, gradually broadening indications. With accu-
mulating data, it has become clear that the treatment benefits 
are not homogenous among all the patients. Response rates 
to single- agent PD- 1/PDL- 1 inhibitors are variable with 40% 
in melanoma, 25% in non- small cell lung cancer (NSCLC), 
and 19% in renal cell carcinoma.3– 7 This highlights the im-
portance of finding a discriminating biomarker that could 
predict the outcomes of ICI therapy. PDL1 expression, mi-
crosatellite instability status, tumor mutation burden, CD8+ 
T cell infiltration are some of the extensively studied predic-
tive biomarkers; however, with conflicting data in different 
studies.8,9 The variation in patient selection criteria, assays 
and determinants used to assess PDL1 expression could have 
contributed to this discrepancy.10 Immune- related adverse 
events (iRAEs) from ICI therapy affect patients differently, 
and it is critical to understand its determinants. Evaluation of 
the current conflicting data on the association between the in-
cidence of iRAEs and response to ICI is equally essential.11,12 
Most importantly, there is a lack of real- world data on re-
sponse to ICI response and patient outcomes in diverse popu-
lations. Real- world datasets, which reveal genomic profiling 
and clinical outcomes, provide an important tool to recognize 
inferences on biomarkers of response and resistance. These 
data could also enable the discovery of novel biomarkers not 
be seen in the highly selective clinical trials. Randomized 
controlled trials with strict entry requirements to guarantee 
internal stability can lead to the loss of external scalability. 
This could be due to the exclusion of patients with poor prog-
nosis, older patients, patients with brain metastases, and an 
ECOG score of 2 or more. Mutational analyses have now 
enabled subclassification of tumors into molecularly defined 
subtypes. Evaluation of ICI response and resistance in tumors 
that demonstrate these mutations is a muddy landscape with 
little valuable data.
Our study aims to assess various molecular markers and 
their impact on progression- free survival and radiological re-
sponse rates with ICI therapy. This assessment is especially 
important in our population as Kentucky has an exceedingly 
high- smoking prevalence of 24.6% among adults and has the 
highest incidence of cancer in the United States. This popu-
lation could present a varied biomarker profile and responses 
compared to that seen in clinical trials and provide insight 
into new biomarkers. In recent studies, a higher tumor mu-
tational burden was identified among patients who smoke, 
with the possibility of smoking- specific mutations as drivers 
for oncogenesis.13 Although the results might not be general-
izable, they can give potential information to further search 
for biomarkers and help identify specific signatures in this 
high- risk population.
2 |  METHODOLOGY
We conducted a retrospective analysis of all patients with 
metastatic solid tumors above 18 years of age who received 
ICI in our institution between January 2016 and January 2020. 
The cancer center is the highest volume cancer center and 
the only National Cancer Institute designated cancer center 
in the state of Kentucky. The institutional review board ap-
proved the study. Demographics, treatment plans, and out-
comes were obtained by reviewing electronic health records 
and Kentucky Cancer Registry (KCR). US Food and Drug 
administration approved next- generation sequencing (NGS) 
platforms- FoundationOne® CDx and FoundationOne® Dx 
panels were used for mutational analysis of tumor sam-
ples. These tests can be used to detect substitutions, inser-
tions, deletions, and copy number alterations in 324 genes 
and selected gene rearrangements. The system also esti-
mates tumor mutational burden and microsatellite instabil-
ity (MSI) using DNA isolated from tumor tissue specimens. 
MSI status is determined by a genome- wide analysis of 95 
microsatellite loci. PDL1 expression is tested using PD- L1 
22C3 IHC with interpretation using Tumor Proportion Score 
(TPS). Tumor mutational burden (TMB) is reported as muta-
tions per megabase (mut/Mb) unit. It is further subdivided 
into high (≥20Muts/Mb), intermediate (6– 19 Muts/Mb), and 
low (≤5Muts/Mb). Patients with indeterminate TMB were 
excluded from the analysis. For analysis, TMB was dichoto-
mized as high and low to intermediate. Only genomic altera-
tions of known significance were included in the analysis. 
One investigator assessed radiologic response to ICI therapy 
for all patients using Response Evaluation Criteria for Solid 
Tumors (RECIST) 1.1 by analyzing radiology reports and 
image records. Response categories were divided into com-
plete response (CR), partial response (PR), stable disease 
(SD), and progression of disease (PD). 146 patients who did 
not have complete molecular and radiological information or 
2056 |   JACOB et Al.
lost to follow up before complete evaluation were excluded 
from the analysis. Progression- free survival (PFS), radio-
logical response, and autoimmune side effects were analyzed 
with various molecular biomarkers.
2.1 | Statistical analysis
Categorical variables were analyzed as percentages and con-
tinuous variables as means or medians. Statistical analysis was 
performed using SPSS 26.0 and JMP 14 software. Logistic 
regression, Fisher's exact test, Kaplan- Meier method, log- 
rank test, and Cox regression were used to analyze clinical 
features and efficacy outcomes. p- value <0.05 was consid-
ered to be statistically significant. Overall survival was not 
considered for analysis as there were only eight deaths, prob-
ably due to a shorter period of follow- up.
3 |  RESULTS
3.1 | Patient characteristics
Sixty nine patients had genomic and radiologic data for 
inclusion in the study. The median follow- up period was 
63 weeks. 36 (52.2%) subjects were male. The mean age of 
the study population was 62 (range: 27– 95 years), and 14.5% 
were over 75 years of age. 91.3% were of Caucasian ethnic-
ity. There was a very high prevalence of smoking (78.3%), 
and 66.7% of the never- smokers also had recorded second-
hand smoke exposure. 13% of the study population also used 
e- cigarettes. 100% of patients with NSCLC were smokers. 
45% of patients were from Appalachian region and 60% from 
rural counties. NSCLC constituted the majority (37.7%) of 
the tumor types included in the study, followed by squamous 
cell cancer (SCC) of the head and neck and melanoma. 23% 
of the patients had brain metastasis at diagnosis or on progres-
sion. 100% of patients with NSCLC were smokers (Table 1).
3.2 | Treatment
Mean time to ICI use from diagnosis was 69.5  weeks. 
Pembrolizumab was the most commonly used ICI (65%) fol-
lowed by nivolumab and ipilimumab (16% each), and most 
patients received single- agent immunotherapy (77%). 40 pa-
tients (58%) received ICI treatment as first line therapy, 23 
(33.3%) as second line and 6 (8.9%) received as third line for 
FDA- approved indications. None of the patients received ICI 
for high- TMB or MSI- H status. About half of these patients 
(47.8%) had iRAEs with grade 3/4 adverse events reported at 
14.4%. Hyperprogression, which is treatment failure within 
two months of treatment initiation or ≥50% increase in tumor 
burden in 2 diameters or ≥100% in one diameter, was pre-
sent in six patients (8.7%). Radiologic pseudo- progression 
was found only in 2 patients, one with NSCLC and one with 
squamous cell cancer of head and neck (Table 2).
3.3 | Biomarkers and Mutational assay
The majority of the tumor samples (65.2%) had a positive PDL- 1 
expression represented as a tumor proportion score (TPS) ≥1%. 
90% of the tumors were microsatellite stable, and the average 
TMB was 12.6 (range 0– 117). 13% of patients had TMB ≥20 
mut/Mb and 46.4% tumors had TMB between 6– 19 mut/Mb. 
The NGS panel detected TP53 as the most common (62.3%) 
tumor mutation. It was followed by CDKN1B/2A (40.5%), 
NOTCH (33.3%), and PIK3CA/2B (33.3%) mutations. STK11 
mutation was found in 16% of patients. TMB did not correlate 
to smoking status or pack years (Table 2, Figure 1, Figure 2).
T A B L E  1  Baseline characteristics of the study population
Characteristics Total (%)
Age group
18– 64 40 (58)
65– 74 19 (27.5)
≥ 75 10 (14.5)
Male: Female 36 (52.2): 33 (47.8)
Race
Caucasian 63 (91.3)









Small Cell lung Cancer 5 (7.2)
Hepatobiliary 2 (2.9)
Breast 2 (2.9)
Ovary and uterus 2 (2.9)
Thyroid 2 (2.9)
Merkel Cell 1 (1.4)
Unknown primary 1 (1.4)
Tobacco use
Current/previous use 54 (78.3)
Never used 15 (21.7)
Secondhand exposure 10 (14.5)
Abbreviations: NSCLC, Non- small cell lung cancer; SCC, Squamous cell 
carcinoma.
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Tumor mutations commonly associated with smoking 
(BRAF, JAK2, JAK3, NOTCH1, TP53) were higher in the 
study population compared to cBioPortal database metastatic 
solid tumor cohorts.14,15 There was similar difference on evalu-
ation of genomic alterations involving PIK3/AKT/mTOR path-
way and alterations implicated in homologous recombinant 
repair. BRCA1, MTOR, and PTEN mutations were, however, 
less common in the study group compared to the trial cohort.
3.4 | Response and outcome by PDL1 
expression and TMB
TMB was not associated with smoking status or pack years. 
Patients with high TMB (≥20 mut/Mb) had an overall radio-
logic response rate (CR+PR) of 55.6% compared to 51.7% in 
low- intermediate TMB group (p  =  0.83). Median PFS was 
higher in high TMB compared to the low- intermediate group 
and the results reached statistical significance (median not 
reached vs. 26 weeks; HR=0.37. 95%CI 0.13, 1.05). Although 
there was improvement in PFS (median 53 vs. 26  weeks, 
HR=1, 95%CI 0.37, 2.72) this was not statistically significant 
when the FDA- approved cut off of ≥10mut/Mb for ICI use was 
used to identify high TMB. Radiologic responders were identi-
cal in both groups. (0.52% vs. 0.52%, OR = 1, p = 1). PDL1 
expression was not associated with radiologic response, but 
there was a trend toward improved PFS in patients with tumors 
expressing PDL1 (median 18 vs. 40 weeks. HR = 1.43. 95%CI 
0.93, 4.46). There was no significant correlation between size 
change of the target lesion with ICI therapy and absolute TMB 
values (R2 = 0.023) (Figure 3, Table 3).
3.5 | Response and outcome by 
tumor mutations
The presence of BRAF mutation conferred shorter PFS with 
immunotherapy (median 17 vs. 39 weeks. HR = 0.35. 95%CI 
0.14, 0.91) but had no significant association with radiologic 
response. STK11 mutation did not have a significant impact 
on PFS (median 30 vs. 39 weeks, HR=0.88. 95%CI 0.39, 2.0) 
or radiologic response (OR = 1.61, p = 0.58). Presence of 
KRAS mutations also did not show significant impact on PFS 
(median 48 vs. 38 weeks, HR=1.27, 95%CI 0.62, 2.58) or ra-
diologic response (OR = 1.12, p = 0.84) (Figure 3, Table 3).
Statistically significant improvement in PFS was observed 
in the PIK3 mutated (PIK3CA/PIK3C2B) group (median 123 
vs. 23 weeks. HR = 2.51. 95%CI 1.23, 5.14). (Figure 3) This 
was independent of TMB status or PDL1 expression status 
(HR 3.24, p = 0.016). Patients with PIK3 mutations had a 
higher overall response rate (ORR) than the unmutated group 
(69.6% vs. 43.5%, OR 0.34; p = 0.045). PIK3 mutated pa-
tients also had a higher risk of developing IRAEs (73.9% vs. 
37%, OR = 0.21 p = 0.005), but the presence of mutation did 
not associate with TMB, PDL1 expression or microsatellite 
stability status ruling out collinearity.
There was a difference in ORR with FGFR mutations 
(72.2% vs 45.1%, OR 0.32; p = 0.05) and ROS1 mutation 
(90% vs. 45.8%, OR 0.09; p = 0.029). With FGFR mutation, 
there was a trend toward statistical significance for PFS with 
immunotherapy (median 39 vs. 30 weeks. HR = 1.84. 95%CI 
0.90, 3.76), which was not seen with ROS1 mutation.
3.6 | Response and outcome (others)
There was no statistically significant difference in radiologic 
response and PFS with ICI therapy based on smoking status, 
ICI drug, MSS status, incidence of IRAEs, or age (below and 
above 65 years of age).










Grade 1 7 (10.1)
Grade 2 16 (23.2)
Grade 3/4 10 (14.4)
Tumor Mutational Burden
≥20 mut/Mb 9 (13)
6– 19 mut/Mb 32 (46.4)
≤ 5 mut/Mb 28 (40.6)
PDL1 tumor proportion score
0 18 (26.1)
1– 49% 28 (40.6)
≥50 17 (24.6)
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4 |  DISCUSSION
Our study was aimed at evaluating clinicopathologic char-
acteristics and outcomes in a subset of population with the 
highest incidence of cancer in the country and often under-
represented in clinical trials. The outcomes with immuno-
therapy, incidence of iRAEs and biomarker profiling of these 
patients are poorly understood. With the current data avail-
able only from a carefully selected clinical trial population, 
many biomarkers that could be effective in such selected 
population might have been overlooked. The study also 
looked at potential markers of immunotherapy response in 
this patient population (90).
The prevalence of smoking and secondhand smoke ex-
posure was high in the study group. The study did not find 
association of smoking status with TMB. Nearly half (47.8%) 
of the patients experienced any degree of IRAEs. The median 
tumor mutation burden was 12.6 mutations/Mb which was 
F I G U R E  1  Percentage of patients with 
mutations in cBioPortal and this study. (A) 
NSCLC cohort in both studies with genomic 
alterations associated with smoking. (B) 
Genomic alterations involving PIK3/AKT/
mTOR pathway. (C) Alterations implicated 
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at least twofold to fourfold compared to other similar stud-
ies.16,17 Our results show the prevalence of PDL1 expression, 
TMB in our study group are similar to ones seen in previous 
clinical trials. Compared to historic cohorts, the prevalence 
of PIK3/AKT/mTOR pathway and homologous recombinant 
repair alterations were higher in the study group. Smoking 
associated tumor genomic alterations was also significantly 
higher compared to similar cohorts.
High- tumor mutational burden, and the presence of PIK3 
mutation conferred better progression- free survival with im-
munotherapy across cancer types. This PFS benefit seen in 
PIK3 mutated patients was independent of PDL1 status or 
TMB. The effect of PDL1 expression and FGFR mutation 
on PFS trended toward statistical significance. The presence 
of PIK3 mutation and ROS1 mutation also had a statistically 
significant favorable impact on the best overall radiologic 
tumor response while with FGFR mutation, this trended to-
ward statistical significance. The high incidence of IRAEs 
in the PIK3 mutated group also points toward possible in-
creased PDL1 inhibitor activity. STK11 mutation, which was 
previously implicated in immunotherapy resistance, did not 
significantly affect immunotherapy response or outcomes. 
Although the absolute numbers were small, patients with 
BRAF mutations had a poor outcome with immune therapy.
The PIK3/AKT/mTOR (PAM) pathway is considered a 
master regulator of cancer and plays a vital role in tumor 
growth, proliferation, angiogenesis, and cell survival.18 
PIK3CA is the most studied among PIK3 mutations, with 
amplification or clustering of somatic mutations occurring 
in up to 30% of endometrial, breast, ovarian, and colon can-
cers while PIK3CB is found in thyroid and lung cancers.19 
PI3KCA/CB mutations are primarily activating, while the 
F I G U R E  2  Mutational analysis of patients receiving immunotherapy grouped based on radiologic response, in the order of mutational load and 
frequency of mutations
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pathway inhibiting PIK3R1 mutations are mostly inactivat-
ing.20 These mutations were also implicated in chemother-
apy and HER2 blocker resistance.21,22 The pathway, more 
importantly, plays a stimulatory role in PDL1 transcription 
and expression on tumor cells.23,24 Despite the abundance 
of laboratory and animal data, clinical data linking various 
PIK3 protein mutations and immunotherapy responses are 
lacking.
The study has limitations with small sample size, short 
follow- up period and being a single- center study. Most of 
the patients who received ICI at the institution were not in-
cluded in the final analysis due to incomplete data or loss 
to follow up making the need of prospective trials import-
ant. The results should prompt further evaluation of these 
potential biomarkers and more widespread real- world data 
publications.
F I G U R E  3  Kaplan- Meier graphs depicting progression- free survival in patients based on tumor samples showing (A) High TMB and low/
intermediate TMB; (B) PDL1 expression; (C) Presence of IRAEs; (D) Presence of PIK3 mutation; (E) Presence of FGFR mutation; (F) Presence of 
BRAF mutation
p= 0.407 by log-rank test
p=0.065 by log-rank testp= 0.49 by log-rank test
p=0.009 by log-rank test
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5 |  CONCLUSION
The study characterizes the ICI response, IRAEs, and 
mutational profile in a population with high prevalence 
of smoking and the highest cancer incidence and mortal-
ity in the country. The prevalence of mutations associated 
with smoking, homologous recombinant repair and PIK3/
AKT/mTOR pathway were higher in the study group com-
pared to similar cohorts. The previously reported positive 
evidence for TMB and PDL1 expression as ICI biomarkers 
were replicated in this study. The presence of PIK3 muta-
tion conferred better progression- free survival and radio-
logic response with immunotherapy across cancer types. 
Although conflicting evidence exists on using these mark-
ers across cancers for patient selection, these could still 
be relevant in specific target populations with significant 
risk factors like smoking in our population. More extensive 
studies and long- term follow- up data are needed to con-
firm the clinical validity and role of individual mutations 
in immunotherapy response. Furthermore, more real- world 
data is needed to help identify specific biomarkers based 
on population and risk factors.
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rate OR 95% CI
All patients 69 36 (52.2) 33 (47.8) 52.2%
Age <65 40 19 (47.5) 21 (52.5) 47.5% 0.64 (0.24– 1.68)
Age >65 29 17 (58.6) 12 (41.4) 58.6%
Male 36 16 (44.4) 20 (55.6) 44.4% 1.92 (0.74– 5.02)
Female 33 20 (60.6) 13 (39.4) 60.6%
Smoker 54 26 (48.1) 28 (51.9) 48.1% 2.15 (0.64– 7.14)
Non- smoker 15 10 (66.7) 5 (33.1) 66.7%
IRAE present 34 19 (55.9) 15 (44.1) 55.9% 0.75 (0.29– 1.92)
IRAE absent 35 17 (48.6) 18 (51.4) 48.6%
High TMB 9 5 (55.6) 4 (44.4) 55.6% 1.17 (0.29– 4.78)
Low/int TMB 60 31 (51.7) 29 (48.3) 51.7%
TMB <10 46 24 (52.2) 22 (47.8) 52.2% 1.00 (0.36– 2.72)
TMB ≥10 23 12 (52.2) 11 (47.8) 52.2%
PDL1 0% 18 6 (33.3) 12 (64.7) 33.3% 0.45 (0.12– 1.68)
PDL1 >1% 45 25 (55.6) 20 (44.4) 55.6%
PIK3 mutated 23 16 (69.6) 7 (30.4) 69.6% 0.34 (0.12– 0.97)
PIK3 wild type 46 20 (43.5) 26 (56.5) 43.5%
FGFR mutated 16 13 (72.2) 5 (27.8) 72.2% 0.32 (0.98– 1.01)
FGFR wild type 51 23 (45.1) 28 (54.9) 45.1%
ROS1 mutated 10 9 (90.0) 1 (10.0) 90.0% 0.09 (0.01– 0.79)
ROS1 wild type 59 27 (45.8) 32 (54.2) 45.8%
BRAF mutated 5 3 (60.0) 2 (40.0) 60.0% 0.71 (0.11– 4.54)
BRAF wild type 64 33 (51.6) 31 (48.4) 51.6%
STK 11 mutation 11 4 (36.4) 7 (63.6) 36.4% 2.15 (0.57– 8.17)
STK11 wild type 58 32 (55.2) 26 (44.8) 55.2%
Bold indicates statistically significant values.
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